Moh Family Foundation Professor of Emerging Infections and Global Health. Director, Pandemic Sciences Institute, University of Oxford, UK.
Joined February 2014
- Tweets1.6K
- Following276
- Followers12.3K
- Likes701
PSI Director calls for stronger pandemic intelligence after UK Covid-19 Inquiry Module 2 report published psi.ox.ac.uk/news-and-opinio…
Want to make a meaningful impact in global health security?
DPhil (PhD) in infection prevention control and biocontainment measures for high consequence infectious diseases. ndm.ox.ac.uk/study/dphil-the…
⏰ Application deadline: 10th October, 5pm UK time. Jan 2026 start!
Peter Horby @peterhorby.bsky.social retweeted
Simple new method that measures viral clearance means promising antibody treatments for #Covid & flu can be quickly assessed for effectiveness, say researchers in @TheLancet, & save time, money, lives in next pandemic
bit.ly/45HeRY7
Full paper: bit.ly/4fw88DR
ALT Training during a site initiation visit (SIV) of the PLATCOV (COVID) and AD ASTRA (flu) clinical trials in Kathmandu, Nepal in June 2024. © MORU. Photo: Ellen Beer.
Peter Horby @peterhorby.bsky.social retweeted
World’s first rigorous clinical trial of treatments for bubonic #plague:
UK & #Madagascar researchers find treatment at home with oral antibiotics highly effective & safe low-cost alternative to injections
👉lshtm.ac.uk/newsevents/news/…
ALT Healthcare professionals in masks and gowns treating a patient with plague
Fantastic to see this published - first ever trial of treatment for bubonic plague
Huge thanks to the wonderful team in Madagascar #InstitutPasteur and our funders #FCDO #Wellcome
An important but incredibly challenging study - everyone deserves to benefit from science.
Data on treatments for bubonic plague are limited. In this open-label, randomized, controlled trial in Madagascar, ciprofloxacin monotherapy was noninferior to a standard aminoglycoside–ciprofloxacin regimen. Full IMASOY trial results and Research Summary: nej.md/3Ugs0kx
ALT The New England Journal of Medicine Ciprofloxacin vs. Aminoglycoside–Ciprofloxacin in Bubonic Plague A Research Summary based on Randremanana RV et al. | 10.1056/NEJMoa2413772 | Published on August 7, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Fantastic morning discussing pandemic prevention, One Health and system-wide approaches. Now debating the Pandemic Agreement and what it means in practice. linkedin.com/posts/pandemic-…
Peter Horby @peterhorby.bsky.social retweeted
In a collaborative new study, researchers at @PSIOxford have partnered with global colleagues to discover how #AI could accelerate infectious disease research and help to prepare the world for the next pandemic 🔬🦠🤖
Find out more 👉 ndm.ox.ac.uk/news/advances-i…
Peter Horby @peterhorby.bsky.social retweeted
REMAP-CAP's @DerdeLennie adds her voice to a beautiful celebration of #InternationalDayofWomenandGirlsinScience 👇
This Post is from an account that no longer exists. Learn more
Peter Horby @peterhorby.bsky.social retweeted
New publication in The Lancet: Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu. A prospective observational cohort study at Kamituga General Hospital.
sciencedirect.com/science/ar…
There seem to be THREE simultaneous filovirus outbreaks - Marburg in Tanzania, Ebola in DRC (most likely culprit Zaire Ebolavirus) and Sudan Ebolavirus in Uganda.
We need adequately funded public health and research and development programmes and support.
Permanent Secretary, Dr. @DianaAtwine addresses the media this afternoon.
“An outbreak of Sudan Ebola Virus Disease has been confirmed in Kampala, Uganda following confirmation from 3 National Reference Laboratories.”
🔥 RECOVERY sotrovimab result now available.
Despite widespread vaccination and natural immunity, sotrovimab reduced mortality in COVID-19 inpatients with high levels of SARS-CoV-2 antigen.
medrxiv.org/content/10.1101/…
Peter Horby @peterhorby.bsky.social retweeted
As #Tanzania responds to the confirmed outbreak of #Marburg virus disease, @WHO is working closely with the national health authorities to reinforce control measures to halt the outbreak as soon as possible and protect the health of the population.
afro.who.int/countries/unite…
Marburg raises its head again: so soon after Rwanda outbreak. There are no approved treatments or vaccines for Marburg - from each outbreak we need to incrementally gather the data we need for effective control and treatment.
WHO informed its Member States and International Health Regulation State Parties of an outbreak of suspected Marburg Virus Disease in the Kagera region of #Tanzania
So far, we are aware of 9 suspected cases incl. 8 deaths across 2 districts.
WHO risk assessment of this suspected outbreak:
National level: High
Regional level: High
Global level: Low
More bit.ly/4haNl8m
Controversial COVID study that promoted unproven treatment retracted after four-year saga nature.com/articles/d41586-0…
Ironic that the co-authors complain they were “victims of cyber-harassment” - they should try being on the receiving end of HCQ believers, including Raoult himself.
An extraordinarily strong lesson on the importance of good science, critical thinking, and being truly objective.
The damage done to trust and to patients by the hydroxycholoroquine debacle should never be repeated.
Would love to know the reasons for retraction.
Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted.
So grateful to all the people who helped with the RECOVERY trial, allowing us to debunk the myth of hydroxychloroquine for severe COVID-19
science.org/content/article/…
Peter Horby @peterhorby.bsky.social retweeted
Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted.
So grateful to all the people who helped with the RECOVERY trial, allowing us to debunk the myth of hydroxychloroquine for severe COVID-19
science.org/content/article/…
Md Zakiul Hassan recognised as 2024 ISID Emerging Leader ndm.ox.ac.uk/news/md-zakiul-…
